TriSalus Life Sciences (NASDAQ:TLSI) Upgraded at Zacks Research

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by investment analysts at Zacks Research to a “hold” rating in a report released on Thursday, Zacks reports.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Lake Street Capital cut their target price on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, HC Wainwright started coverage on TriSalus Life Sciences in a research note on Wednesday. They issued a “buy” rating and a $11.00 target price for the company. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Hold” and an average price target of $8.67.

TriSalus Life Sciences Stock Performance

TLSI opened at $4.66 on Thursday. TriSalus Life Sciences has a 52-week low of $2.20 and a 52-week high of $7.95. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. The company has a market cap of $286.96 million, a P/E ratio of -3.58 and a beta of 0.44. The firm’s 50-day moving average price is $4.75 and its 200-day moving average price is $4.33.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). The company had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million. As a group, equities analysts anticipate that TriSalus Life Sciences will post -0.31 EPS for the current fiscal year.

Institutional Trading of TriSalus Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in shares of TriSalus Life Sciences in the first quarter worth $187,000. Geode Capital Management LLC grew its holdings in TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after acquiring an additional 235,627 shares during the period. JPMorgan Chase & Co. grew its holdings in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the period. New York State Common Retirement Fund purchased a new position in TriSalus Life Sciences during the second quarter valued at approximately $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in TriSalus Life Sciences during the second quarter valued at approximately $47,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and an $11.00 price target, implying approximately 135.5% upside from the referenced $4.67 share price. The recommendation provides new analyst visibility and supports the bullish case for TLSI. HC Wainwright initiates coverage of TriSalus Life Sciences with a Buy rating
• Positive Sentiment: HC Wainwright’s forecasts point to improving long-term profitability. The firm estimates EPS of $0.09 in fiscal 2028, $0.57 in 2029 and $1.02 in 2030, suggesting expectations for substantial earnings growth as TriSalus expands its business.
• Neutral Sentiment: The analyst still expects losses through fiscal 2027, including EPS of negative $0.31 for 2026 and negative $0.28 for 2027. Quarterly loss estimates improve from negative $0.12 in the third quarter of 2026 to negative $0.02 in the fourth quarter of 2027, indicating gradual progress but continued reliance on execution and financing before profitability.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 10, unchanged from the prior period. This indicates no measurable short-squeeze setup, but also no significant disclosed bearish short positioning.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.